Immunoglobulin G1 [234-alanine,235-glutamic acid,237-alanine,330-serine,331-serine], anti-(human C5a anaphylatoxin chemotactic receptor 1) (human monoclonal TJ210001 ?1-chain), disulfide with human monoclonal TJ210001 ?-chain, dimer
Metastatic Cancer
I-Mab Biopharma US Limitedmonoclonal_antibodyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
276 Active assets in the Metastatic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 3 | BB |
Irinotecan Incyte Corporation | Phase 3 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | BB |
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [234-alanine,235-glutamic acid,237-alanine,330-serine,331-serine], anti-(human C5a anaphylatoxin chemotactic receptor 1) (human monoclonal TJ210001 ?1-chain), disulfide with human monoclonal TJ210001 ?-chain, dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →